<DOC>
	<DOCNO>NCT01801709</DOCNO>
	<brief_summary>The objective open-label , single arm , monocentric , phase I/II clinical study ass safety efficacy ARSA gene transfer brain child affect early onset form Metachromatic Leukodystrophy ( MLD ) . For purpose , adeno-associated virus serotype rh.10 ( AAVrh.10 ) vector use transfer ARSA cDNA cod Arylsulfatase A ( ARSA ) enzyme brain child . Five patient early onset form MLD , age range 6 month 4 year , include protocol follow 24 month . Patients select presymptomatic early stage disease , follow clinical , neuropsychological brain imaging criterion . Twelve simultaneous injection investigational medicinal product perform white matter brain hemisphere , 6 image-guided track , 2 deposit per track . A low dose ( 1x10EXP12 vg total ) administer first 2 patient , last 3 receive high dose ( 4x10EXP12 vg total ) . Safety efficiency evaluate base clinical , neuropsychological , radiological , electrophysiological biological parameter .</brief_summary>
	<brief_title>Intracerebral Gene Therapy Children With Early Onset Forms Metachromatic Leukodystrophy</brief_title>
	<detailed_description />
	<mesh_term>Leukodystrophy , Metachromatic</mesh_term>
	<criteria>Boys girl early onset form MLD . Age 6 month 5 year , inclusive Diagnostic MLD base measurement ARSA activity leukocytes accumulation sulfatides urine , along normal activity least one sulfatase Informed consent sign willingness monitoring 2 year treatment . Normal value standard laboratory test Absence ARSA protein immunocytochemistry and/or ELISA Gestational age &lt; 32 week amenorrhoea age &lt; 1 year Brain atrophy subdural space &gt; 10 mm frontal region Performance IQ &lt; 50 WPPSIIII cognitive function &lt; 3rd percentile Bayley 's test infant development If age &gt; 16 month inclusion , inability walk step alone OR inability walk step support one side along inability stand alone Impossibility anesthesia Malignancy , cardiac malformation , liver dysfunction , renal dysfunction Neurological disorder , except benign , related MLD . Any clinically significant untreated comorbid medical condition determine clinical investigator , include cardiac , pulmonary kidney disease . MRI impossibility Evoked potential impossibility Participation another therapeutic clinical trial MLD . Unaffiliated French National Health Insurance .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Brain Gene Therapy</keyword>
	<keyword>Adeno Associated vector</keyword>
	<keyword>Lysosomal sotage disease</keyword>
	<keyword>Leukodystrophies</keyword>
</DOC>